KOSDAQBiotech & Pharma138610

Nibec

₩12,480▲ 1.30%2026-11-18 close
Market Cap
₩141.9B
Turnover
₩87,513,820
Volume
7K
Shares out.
11.4M
PER
—
PBR
3.2×
EPS
-₩244
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

After licensing income, core profitability is the test

Nibec swung to an annual profit in 2025 on upfront licensing payments, but the 3Q 2026 operating loss shows quarterly profitability is still unsettled, so a recovery in the core regenerative materials business is the next checkpoint.

  1. 1

    Disclosed 2025 revenue was KRW 32.7 billion and operating profit was KRW 5.03 billion, a swing to profit. An upfront payment of about KRW 10.9 billion booked in 2Q 2025 was the main driver of the increase.

  2. 2

    Quarterly operating results in 2026 were a profit in 1Q (KRW 137 million), a profit in 2Q (KRW 103 million), and an operating loss in 3Q (KRW 783 million). 3Q revenue was KRW 4.49 billion, down 13.0% year on year.

  3. 3

    Over the last four quarters (4Q 2025 to 3Q 2026), the sum of net losses attributable to controlling shareholders was KRW 2.72 billion, so PER is not calculated.

  4. 4

    In peptides, the NP-201 fibrosis candidate has been licensed to a US company (total deal value US$435 million), and the obesity candidate Regenotide is preparing for a US Phase 2 trial.

  5. 5

    The core dental regenerative materials business posted 2Q 2026 core revenue of about KRW 6.0 billion, up 23% year on year, according to a company announcement dated August 14, 2026.

02

Business structure

Nibec's base business is tissue-regeneration biomaterials centered on dental bone graft substitutes and barrier membranes, while the company is also building peptide drug candidates and a drug-delivery platform.

Its base products are the OCS-B bone graft and the collagen-based regenerative material Regenomer, and both received EU Medical Device Regulation (MDR) certification in March 2026.

Sales rely on a partner network with global implant companies Straumann and Nobel Biocare, with exports to Europe, the United States and China. In July 2026 OCS-B Collagen received a product license in Brazil, allowing supply into Latin America's largest dental implant market.

In China, OCS-B Collagen completed clinical trials and a product license application was submitted to the National Medical Products Administration (NMPA).

On the peptide side, Nibec licensed the fibrosis candidate NP-201 to a private US company in May 2025, with a total deal value of US$435 million and an upfront payment of about US$8 million. Development milestones of up to US$427 million were disclosed.

After the license, decisions on clinical development rest with the licensee. The obesity and sarcopenia candidate Regenotide is preparing for a US Phase 2 trial, and the company is also expanding peptide active pharmaceutical ingredient (API) and contract development and manufacturing (CDMO) work.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.2B-₩1B−19.2%
2025Q4₩6.1B-₩1.2B−18.8%
2026Q1₩5.2B₩100M2.6%
2026Q2₩6.1B₩100M1.7%
2026Q3₩4.5B-₩800M−17.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩21.7B₩600M-₩3.8B3.0%−11.4%114.7%
2023₩15.7B-₩2.2B-₩6.3B−14.2%−21.8%131.6%
2024₩24.6B-₩4.9B-₩9.3B−20.1%−28.9%93.8%
2025₩32.7B₩5B₩4.6B15.4%10.1%37.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue fell 27.5% from KRW 21.7 billion in 2022 to KRW 15.7 billion in 2023, then rose to KRW 24.6 billion in 2024 (up 56.3% year on year) and KRW 32.7 billion in 2025 (up 33.3% year on year), growing for two consecutive years. Among 2022 to 2025, 2025 was the largest year and 2023 the smallest.

Operating profit of KRW 646 million in 2022 turned into an operating loss of KRW 2.23 billion in 2023, and losses widened to an operating loss of KRW 4.93 billion in 2024. In 2025 operating profit was KRW 5.03 billion, a swing to profit, and the operating margin was 15.4%.

The operating margin moved from 3.0% in 2022 to -14.2% in 2023 and -20.1% in 2024 before reaching 15.4% in 2025. Over the same period the debt-to-equity ratio went from 114.7% to 131.6% and 93.8%, then fell to 37.5% in 2025.

Net loss attributable to controlling shareholders widened from KRW 3.77 billion in 2022 to KRW 6.28 billion in 2023 and KRW 9.33 billion in 2024, then turned to a net profit of KRW 4.64 billion in 2025. Net income including non-controlling interests moved in the same direction, at KRW 4.64 billion in 2025.

The 2025 profit reflects the licensing income the company cites. An upfront payment of about KRW 10.9 billion under the fibrosis licensing deal signed in May 2025 was recognized in 2Q, and that lifted operating profit for the quarter sharply.

Operating cash flow was KRW 5.44 billion in 2022, negative KRW 1.96 billion in 2023, KRW 291 million in 2024 and KRW 5.82 billion in 2025, so it stayed positive except in 2023.

On a quarterly basis, revenue rose from KRW 5.17 billion in 3Q 2025 to KRW 6.14 billion in 4Q 2025, but the operating loss widened from KRW 993 million to KRW 1.15 billion.

Revenue in 1Q 2026 was KRW 5.24 billion, but operating profit of KRW 137 million was a swing to profit, and the company attributed this to a roughly 35% drop in selling, general and administrative expenses.

Revenue in 2Q 2026 was KRW 6.06 billion with operating profit of KRW 103 million, while 3Q 2026 revenue of KRW 4.49 billion fell 25.9% from the prior quarter and an operating loss of KRW 783 million turned the quarter back into a loss. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 2.72 billion.

05

Industry analysis

Demand for dental regenerative materials tracks dental implant procedure volumes, and Nibec's core products reach overseas markets through the distribution networks of global implant companies. The company describes Brazil as Latin America's largest dental implant market and a key target for global implant makers.

The company said the March 2026 MDR certification for OCS-B was the first such approval for an animal-derived bone graft in Korea and the second worldwide. A 2024 report noted that OCS-B holds US FDA and European CE approvals and has a partner network with two of the largest implant companies.

Regulatory certifications help secure new distribution partners, but actual order volumes depend on implant procedure demand and partner sales policies. The China business is being reorganized through its distribution network, so the pace of recovery there is hard to gauge.

The peptide drug business is shaped by licensing market conditions, and licensing income tends to cluster around signing dates, which makes quarterly revenue move sharply. In competitive terms, Nibec is described as pairing a core dental regenerative materials business with a peptide drug and drug-delivery platform.

Compared with listed peptide drug developers, Nibec has a smaller core sales base and relies more heavily on licensing income.

06

Outlook

The next steps the company has described are clinical progress for its peptide pipeline and wider overseas sales. Regenotide is preparing for a US Phase 2 trial, and the company is reviewing development strategies that include monotherapy and combination use with GLP-1 class drugs.

At BIO-Europe 2026 in Cologne, held November 9 to 11, 2026, Nibec presented Regenotide and a cardiorenal candidate as targets for licensing. Because decisions on follow-on clinical development of NP-201 rest with the US licensee, the timing the company can control directly is limited.

In the 1b/2a trial results disclosed in January 2026, no serious drug-related adverse events were reported, and the company said the results support advancing to Phase 2 development.

The NP-201 active ingredient received confirmation of EU-GMP qualified person compliance in August 2026, establishing a supply base for European clinical use.

In the core business, the company is pushing European sales on the basis of MDR certifications for OCS-B and Regenomer, including through EAO 2026 in September 2026. OCS-B Collagen in China is under product license review. In late 2025, brokers expected Nibec to enter a turnaround in 2026.

However, the swing to an operating loss in 3Q 2026 makes it the next checkpoint whether that expectation carries into results after 4Q.

07

Valuation

PER
—
PBR
3.2×
ROE
-6.1%
EPS
-₩244
BPS
₩4,001
Dividend per share
₩0

When reading the current share price, the first point is that earnings-based multiples offer limited guidance. Net losses attributable to controlling shareholders over the last four quarters mean PER is not calculated, so the price-to-book ratio, which shows the premium over book equity, becomes the main reference.

The price-to-book ratio sits in a range that carries a premium over net assets, with market capitalization well above year-end 2025 total equity, which suggests the market is pricing a substantial share of the future value of the licensing pipeline. Dividend income is not a feature of the current structure.

When comparing with listed peers, it helps first to account for how much earnings depend on one-off licensing income. The key questions in valuation are whether the maximum NP-201 milestones of US$427 million are realized and whether Regenotide enters a US Phase 2 trial.

The 2025 swing to profit came in the year the upfront payment was booked, so how the multiple is read depends on whether quarterly profit converts into core business profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Milestone structure of the NP-201 license

The total deal value for NP-201 is US$435 million, and an upfront payment of about US$8 million (about KRW 10.9 billion) was already recognized in 2Q 2025. Development milestones of up to US$427 million are disclosed, so additional income could arise as clinical and regulatory steps progress.

The company says the deal was structured in four layers: upfront, clinical and approval milestones, commercial milestones, and running royalties.

Certification expansion and core sales recovery

OCS-B and Regenomer received EU MDR certification in March 2026, and OCS-B Collagen received a product license in Brazil in July 2026. The company said core business revenue in 2Q 2026 was about KRW 6.0 billion, up 23% year on year. In 1Q 2026, lower selling, general and administrative expenses turned operating profit positive.

Peptide manufacturing and clinical supply base

The NP-201 active ingredient received confirmation of EU-GMP qualified person compliance in August 2026, establishing a supply base for European clinical use. The 1b/2a trial results disclosed in January 2026 reported no serious adverse events.

Preparation for the Regenotide Phase 2 trial and expansion of peptide CDMO work are presented as follow-on revenue sources built on this manufacturing base.

09

Bear factors

Profit that leaned on one-off income

The 2025 profit relied heavily on the upfront payment recognized in 2Q 2025. The operating loss of KRW 1.15 billion in 4Q 2025 and KRW 783 million in 3Q 2026 show the earnings burden in quarters without one-off income. Revenue in 3Q 2026 also fell 13.0% year on year, so the recovery in core sales is not yet clear.

A range hard to compare on earnings multiples

Net losses attributable to controlling shareholders over the last four quarters total KRW 2.72 billion, a range that is hard to compare on earnings-based multiples. With market capitalization well above total equity, market prices appear to reflect a larger share of pipeline expectations. If quarterly profit swings again, the reading of those expectations could change.

Clinical decision rights and share count risk

Decisions on follow-on clinical development of NP-201 rest with the licensee, which limits the company's direct control. Regenotide is preparing for a US Phase 2 trial, and whether preclinical results carry over to patients can only be tested in clinical studies.

A stock option grant of 580,000 common shares was approved at the March 2026 shareholders' meeting, which could increase the share count over time.

10

Risk factors

Clinical and regulatory timing

Follow-on development of NP-201 depends on the licensee's decisions, and Regenotide is still before its US Phase 2 trial. Whether preclinical results hold in patients can only be tested in clinical studies, so development timelines could slip.

Overseas approvals for dental regenerative materials also vary by country review periods, which shifts the timing of sales.

One-off nature of licensing income

The 2025 profit reflects an upfront payment recognized in 2Q 2025. Milestones and royalties depend on clinical and commercial progress, so their recurrence is limited. Because quarterly results move sharply with licensing timing, quarter-to-quarter profit comparisons are difficult.

Distribution reliance and ownership

Overseas sales of core products depend on the distribution networks of global implant companies including Straumann and Nobel Biocare. The China distribution network was being reorganized as of a September 2025 report.

Shares held by Jung Jong-pyeong and six others total 19.26%, and changes in that ownership could also affect the share price.

11

What to watch next

  1. Late March 2027

    This is the filing deadline for the 2026 annual report of a December fiscal-year company, when full-year 2026 results and 4Q results are finalized. The key check is whether the 3Q 2026 swing to a loss continues into 4Q.

  2. Mid-May 2027 (estimated from the 2026 schedule)

    Release of provisional 1Q 2027 results, to check whether operating profit stays positive and how selling, general and administrative expenses trend.

  3. During 2027 (timing not set)

    Whether Regenotide enters a US Phase 2 trial and whether the GLP-1 combination strategy is confirmed. Trial entry is the starting point for assessing the value of the pipeline.

  4. Timing not set

    Decisions on NP-201 follow-on clinical development and whether milestones are triggered. If a milestone is recognized, one-off income could reappear in quarterly results.

  5. Timing not set

    The NMPA review outcome for OCS-B Collagen in China, which will indicate whether China sales can recover.

12

Overall view

Nibec pairs a core dental regenerative materials business with a peptide licensing pipeline. On a disclosed basis, 2025 revenue was KRW 32.7 billion and operating profit was KRW 5.03 billion, a swing to profit.

However, much of the 2025 profit came from an upfront payment of about KRW 10.9 billion recognized in 2Q 2025. Profits in 1Q and 2Q 2026 and a 23% year-on-year rise in core business revenue in 2Q 2026 suggest the core business is holding up.

On the other side, a 3Q 2026 operating loss of KRW 783 million marked a return to losses, and net losses attributable to controlling shareholders over the last four quarters totaled KRW 2.72 billion, so PER is not calculated.

Bullish factors include the milestone structure of the NP-201 deal, preparation for a US Phase 2 trial for Regenotide, and expanding European and Brazilian approvals.

Bearish factors include reliance on one-off income, quarterly volatility, the licensee holding decision rights on clinical development, and a stock option grant of 580,000 shares.

The next checkpoints are the full-year results to be finalized in the 2026 annual report, whether core profit holds in 1Q 2027, and the timing of Regenotide's clinical entry. This report is for information only and does not present an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. nibec.co.kr
  2. comp.wisereport.co.kr
  3. etoday.co.kr
  4. thebionews.net
  5. thebionews.net
  6. thebionews.net
  7. sedaily.com
  8. thebionews.net
  9. sentv.co.kr
  10. dailyinvest.kr
  11. biotimes.co.kr
  12. newstown.co.kr
  13. vegannews.co.kr
  14. medifonews.com
  15. news1.kr
  16. thebionews.net
  17. m.news.nate.com
  18. m.news.nate.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis